Vivalink's Biometrics Data Platform Supports UCSF Clinical Trial for Hypertrophic Cardiomyopathy (HCM)
CAMPBELL, Calif., March 1, 2023 /PRNewswire/ -- UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink's Biometrics Data Platform. The study, consisting of 70 patients, will evaluate if regimented moderate intensity exercise improves overall exercise capacity and cardiac blood flow.